For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 15,703 | 18,173* | 15,695 | 14,721 |
| General and administrative | 6,630 | 12,580* | 5,953 | 15,967 |
| Total operating expenses | 22,333 | 30,753 | 21,648 | 30,688 |
| Operating loss | -22,333 | -30,753* | -21,648 | -30,688 |
| Loss on long-term investment | - | -1,637* | - | 3,390 |
| Amortization of premium on investments in u.s. treasury securities | - | - | 60 | 34 |
| Other expense, net | -1 | 17* | -9 | -14 |
| Interest expense | 17 | 25* | 22 | 25 |
| Interest income | 2,113 | 2,044* | 1,456 | 1,268 |
| (amortization of premium) accretion of discount on investments in u.s. treasury securities, net | 42 | -28* | - | - |
| Total other income and expense | 2,137 | 371* | 1,365 | 4,585 |
| Loss from operations before income taxes | -20,196 | -30,382 | -20,283 | -26,103 |
| Net loss | -20,196 | -30,382 | -20,283 | -26,103 |
| Net unrealized gain (loss) on investments | -330 | - | - | - |
| Total other comprehensive gain (loss) | -330 | - | - | - |
| Comprehensive loss | -20,526 | - | - | - |
| Basic EPS | -0.25 | -0.539 | -0.33 | -0.6 |
| Diluted EPS | -0.25 | -0.539 | -0.33 | -0.6 |
| Basic Average Shares | 81,183,812 | 56,381,474 | 60,980,867 | 43,573,628 |
| Diluted Average Shares | 81,183,812 | 56,381,474 | 60,980,867 | 43,573,628 |
Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics, Inc. (LXEO)